Progression of ventricular dysfunction after myocardial infarction is prevented by anti-Alzheimer's disease drug, donepezil. by Arikawa, Mikihiko et al.
優秀賞 
26. Progression of ventricular dysfunction after myocardial 
infarction is prevented by anti-Alzheimer's disease drug, donepezil. 
 
Mikihiko Arikawa1, Rajesh G Katare1, Yoshihiko Kakinuma1, Takemi Handa1, Motonori Ando3, 
Fumiyasu Yamasaki2, Takayuki Sato1 
1Department of Cardiovascular Control and 2Department of Clinical Laboratory, Kochi Medical School, Nankoku, 
Japan. 3Department of Science Education, Okayama University, Okayama, Japan. 
 
Introduction: We have previously demonstrated that the vagal nerve stimulation improved survival 
of rats with both acute and chronic heart failure through release of the neurotransmitter acetylcholine. 
Recently donepezil (Aricept), an acetylcholinesterase inhibitor, was also found to improve survival 
rate in rats with chronic heart failure. However the protective effects of donepezil against progression 
of cardiac dysfunction have not yet been elucidated. In this study, we investigated whether donepezil 
prevents progression of left ventricular dysfunction in ischemic chronic heart failure rats. 
 
Methods: Myocardial infarction was constructed by left coronary artery occlusion. The survived rats 
were thereafter divided into sham, untreated (control) and donepezil-treated (5 mg/kg/day in drinking 
water) groups. Six weeks after surgery, left ventricular pressure-volume relationships were 
determined in Langendorff perfused heart preparation. 
 
Results: Compared to the sham group (Ees=1.03 mmHg/µl, ESV=60 µl estimated from linear 
regression analysis at ESP=100 mmHg), the control group showed severe depression of left 
ventricular function (Ees=0.23 mmHg/µl, ESV=320 µl). In contrast, compared with the control 
group, donepezil-treated group exhibited significant improvement of especially left ventricular 
contractility (Ees=0.36 mmHg/µl, ESV=210 µl), but with no differences in an EDP-volume 
relationship and a heart/body weight ratio between control and donepezil-treated groups. 
 
Conclusions: The present results showed that donepezil has a preventive effect on left ventricular 
dysfunction of ischemic failing hearts, suggesting that donepezil can be a new potential candidate for 
a clinically useful drug for chronic heart failure therapy. 
 
 
